Charles Mullighan, MBBS, MD, is the Deputy Director of the St. Jude Children’s Research Comprehensive Cancer Center, Memphis, TN, and Co-Leader of the Hematological Malignancies Program at St. Jude Children’s Research Hospital, Memphis, TN.
Dr Mullighan completed his medical degree at the University of Adelaide, Adelaide, Australia, qualifying in 1993. He then obtained his master’s in medical immunology from King’s College London, London, UK, in 1996, before moving back to Australia to complete his MD in immunogenetics at the University of Adelaide, Adelaide, Australia. In 2008 Dr Mullighan completed his postdoctoral fellowship in the Department of Pathology at the St. Jude Children’s Research Hospital.
Dr Mullighan is a member of the International Society for Experimental Hematology and is an elected member for both the Australian Academy of Health and Medical Sciences as well as the American Society for Clinical Investigation.
Speaking on the genomic analysis of hematologic malignancies
Dr Mullighan’s research focuses on defining the genetic basis for the pathogenesis of hematologic malignancies. His most recent work has been into prognostic mutation constellations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) as well as into the clinical utility of whole-genome sequencing in the context of precision oncology.